StockScouter

The StockScouter® System is a proprietary stock scoring model which covers U.S. companies listed on the major exchanges. The 10 (best) to 1 (worst) score is derived from Fundamental, Technical, Ownership, and Valuation sub-models in combination with a Risk model which assesses the expected risk and return.

StockScouter Screening Tool StockScouter Top 50

CGIX CANCER GENETICS StockScouter® Report

2

StockScouter® Score

CANCER GENETICS, a micro cap value company in the healthcare sector, is expected to underperform the market over the next six months with higher than average risk

10 is the best possible rating. Learn more.

Summary

Positives

  • The enterprise value-to-sales ratio is lower than the average for comparably-sized companies in the StockScouter universe. Positive

 

Concerns

  • The multi-period measure of relative price change and consistency is well below average. Negative
  • The 50-day moving average for CGIX is significantly below its 200-day moving average. Negative
  • Short-term relative price momentum exhibits meaningful weakness. Negative

 

Short-term Outlook

Over the next 1-2 months, StockScouter forecasts that micro cap stocks will be out of favor, value stocks will be out of favor, and healthcare stocks will be out of favor.

Expected Risk/Return

Progress: 100% done.
Progress: 20% done.
Low
High

Core Model Grades

C
N/A
C
F

Previous Ratings

2
3
3